Table 1

Demographic Characteristics (N = 51)

Age (yrs)70.26 ± 9.16
Male44 (86)
Etiology (%)
 Ischemic cardiomyopathy37 (73)
 Nonischemic cardiomyopathy14 (27)
Previous interventions (%)
 CABG or PCI24 (47)
 Valve surgery4 (8)
New York Heart Association functional class
 III32 (63)
 IV17 (35)
Previous CRT-D (%)47 (92)
CRT-P4 (8)
Comorbidities
 Previous stroke8 (16)
 Diabetes11 (22)
 COPD15 (29)
 Renal insufficiency36 (70)
Logistic EuroSCORE29.7 ± 19.4
STS score13.9 ± 14.6
Laboratory findings
 Creatinine (μmol/l)149.5 ± 63.2
 Sodium (mmEq/l)139.74 ± 4.2
 Potassium (mmEq/l)4.25 ± 0.41
 Hemoglobin (g/dl)12.34 ± 1.5
 NT-proBNP (ng/l)3,702 (1,794–8,148)
Month since CRT32.9 ± 25.7
ECG
 Sinus rhythm18 (35)
 QRS width during CRT (ms)149.26 ± 28.84
Echocardiography
 LV end-diastolic diameter (mm)71.0 ± 8.7
 LV end-systolic diameter (mm)60.3 ± 9.8
 LV end-diastolic volume (ml)238.7 ± 72.2
 LV end-systolic volume (ml)174.5 ± 61.0
 LV ejection fraction (%)27.1 ± 8.7
 Mitral regurgitation grade ≥251 (100)
 Systolic pulmonary artery pressure (mm Hg)44.6 ± 11.7
Medication
 ACE inhibitors or ARBs47 (92)
 Beta-blockers45 (88)
 Diuretics50 (98)
 Aldosterone antagonists27 (53)
 Statins26 (51)
 Oral anticoagulation24 (74)

Values are mean ± SD, n (%), or median (25th to 75th percentile).

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; CABG = coronary artery bypass graft; COPD = chronic obstructive pulmonary disease; CRT = cardiac resynchronization therapy; CRT-D = cardiac resynchronization therapy with a defibrillator; CRT-P = cardiac resynchronization therapy pacemaker; ECG = electrocardiography; LV = left ventricular; NT-proBNP = N-terminal pro–B-type natriuretic peptide; PCI = percutaneous coronary intervention; STS = Society of Thoracic Surgeons.